GP531

GP531

G654862-1ml

1ml

10mM in DMSO

-80℃储存

超低温冰袋运输

GP531 is a potent, second-generation adenosine regulating agent, is pharmacologically silent under basal conditions but increases localized endogenous adenosine during ischemia. In Vivo Low-dose GP531 reduces infarct size by 34% compared with vehicle and reduces the extent of the anatomic no-reflow zone by 31% compared with vehicle. Infarct size and zone of no-reflow in the high dose are reduced by 22% and 16%, respectively. GP531 does not affect hemodynamics or blood flow. GP531 is effective at the lower dose in reducing the severity of ischemic/reperfusion injury, without inducing the adverse hemodynamic effects associated with adenosine administration such as bradycardia and hypotension . GP531 infusion has no effect on heart rate or mean aortic pressure but significantly decreases left ventricular end-diastolic pressure, end-diastolic volume, end-systolic volume and end-diastolic wall stress. GP531 significantly increases left ventricular EF, deceleration time of early mitral inflow velocity and the slope of end-systolic PVR without increasing MVO2. MCE has not independently confirmed the accuracy of these methods. They are for reference only. IC50& Target:Adenosine Receptor

GP531 是一种强效的第二代腺苷调节剂，在基础条件下无药理作用，但在缺血时会增加局部内源性腺苷。

142344-87-4(DMSO)

C16H21N5O4

347.37 g/mol

C1=CC=C(C=C1)CNCC2C(C(C(O2)N3C=NC(=C3N)C(=O)N)O)O